The global FIC Single-target Drugs market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

FIC (First in Class) refers to a drug that is first-in-class and is created by gradually synthesizing candidate compounds from scratch by finding new drug targets, mechanisms of action, and molecular structures. Through repeated trials and screening, the drug is ultimately found to meet the requirements of both therapeutic effects and human safety (tolerance, pharmacokinetics).

From a downstream perspective, Hospital accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

FIC Single-target Drugs leading manufacturers including Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, etc., dominate supply; the top five capture approximately % of global revenue, with Pfizer leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global FIC Single-target Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of FIC Single-target Drugs Market Report

Report Metric	Details
Report Name	FIC Single-target Drugs Market
Segment by Type	RORγ Covalent Inhibitors Citron Inhibitors ALK2 Inhibitors GCN2 Agonists Others
Segment by Application	Hospital Clinic Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, Eli Lilly, Agios, Boehringer Ingelheim, Gilead, Mallinckrodt, Phathom, Dermavant Sciences, Polarean lmaging, Marinus
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the FIC Single-target Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the FIC Single-target Drugs Market report?

Ans: The main players in the FIC Single-target Drugs Market are Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, Eli Lilly, Agios, Boehringer Ingelheim, Gilead, Mallinckrodt, Phathom, Dermavant Sciences, Polarean lmaging, Marinus

What are the Application segmentation covered in the FIC Single-target Drugs Market report?

Ans: The Applications covered in the FIC Single-target Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the FIC Single-target Drugs Market report?

Ans: The Types covered in the FIC Single-target Drugs Market report are RORγ Covalent Inhibitors, Citron Inhibitors, ALK2 Inhibitors, GCN2 Agonists, Others

1 Study Coverage

1.1 Introduction to FIC Single-target Drugs: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global FIC Single-target Drugs Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 RORγ Covalent Inhibitors

1.2.3 Citron Inhibitors

1.2.4 ALK2 Inhibitors

1.2.5 GCN2 Agonists

1.2.6 Others

1.3 Market Segmentation by Application

1.3.1 Global FIC Single-target Drugs Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global FIC Single-target Drugs Revenue Estimates and Forecasts 2020-2031

2.2 Global FIC Single-target Drugs Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global FIC Single-target Drugs Sales Estimates and Forecasts 2020-2031

2.4 Global FIC Single-target Drugs Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global FIC Single-target Drugs Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global FIC Single-target Drugs Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 RORγ Covalent Inhibitors Market Size by Manufacturers

3.5.2 Citron Inhibitors Market Size by Manufacturers

3.5.3 ALK2 Inhibitors Market Size by Manufacturers

3.5.4 GCN2 Agonists Market Size by Manufacturers

3.5.5 Others Market Size by Manufacturers

3.6 Global FIC Single-target Drugs Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global FIC Single-target Drugs Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global FIC Single-target Drugs Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global FIC Single-target Drugs Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global FIC Single-target Drugs Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America FIC Single-target Drugs Sales and Revenue by Type (2020-2031)

6.4 North America FIC Single-target Drugs Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America FIC Single-target Drugs Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe FIC Single-target Drugs Sales and Revenue by Type (2020-2031)

7.4 Europe FIC Single-target Drugs Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe FIC Single-target Drugs Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific FIC Single-target Drugs Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific FIC Single-target Drugs Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific FIC Single-target Drugs Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America FIC Single-target Drugs Sales and Revenue by Type (2020-2031)

9.4 Central and South America FIC Single-target Drugs Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America FIC Single-target Drugs Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa FIC Single-target Drugs Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa FIC Single-target Drugs Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa FIC Single-target Drugs Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Pfizer

11.1.1 Pfizer Corporation Information

11.1.2 Pfizer Business Overview

11.1.3 Pfizer FIC Single-target Drugs Product Models, Descriptions and Specifications

11.1.4 Pfizer FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Pfizer FIC Single-target Drugs Sales by Product in 2024

11.1.6 Pfizer FIC Single-target Drugs Sales by Application in 2024

11.1.7 Pfizer FIC Single-target Drugs Sales by Geographic Area in 2024

11.1.8 Pfizer FIC Single-target Drugs SWOT Analysis

11.1.9 Pfizer Recent Developments

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Corporation Information

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson FIC Single-target Drugs Product Models, Descriptions and Specifications

11.2.4 Johnson & Johnson FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 Johnson & Johnson FIC Single-target Drugs Sales by Product in 2024

11.2.6 Johnson & Johnson FIC Single-target Drugs Sales by Application in 2024

11.2.7 Johnson & Johnson FIC Single-target Drugs Sales by Geographic Area in 2024

11.2.8 Johnson & Johnson FIC Single-target Drugs SWOT Analysis

11.2.9 Johnson & Johnson Recent Developments

11.3 Merck

11.3.1 Merck Corporation Information

11.3.2 Merck Business Overview

11.3.3 Merck FIC Single-target Drugs Product Models, Descriptions and Specifications

11.3.4 Merck FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Merck FIC Single-target Drugs Sales by Product in 2024

11.3.6 Merck FIC Single-target Drugs Sales by Application in 2024

11.3.7 Merck FIC Single-target Drugs Sales by Geographic Area in 2024

11.3.8 Merck FIC Single-target Drugs SWOT Analysis

11.3.9 Merck Recent Developments

11.4 Roche

11.4.1 Roche Corporation Information

11.4.2 Roche Business Overview

11.4.3 Roche FIC Single-target Drugs Product Models, Descriptions and Specifications

11.4.4 Roche FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Roche FIC Single-target Drugs Sales by Product in 2024

11.4.6 Roche FIC Single-target Drugs Sales by Application in 2024

11.4.7 Roche FIC Single-target Drugs Sales by Geographic Area in 2024

11.4.8 Roche FIC Single-target Drugs SWOT Analysis

11.4.9 Roche Recent Developments

11.5 Novartis

11.5.1 Novartis Corporation Information

11.5.2 Novartis Business Overview

11.5.3 Novartis FIC Single-target Drugs Product Models, Descriptions and Specifications

11.5.4 Novartis FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 Novartis FIC Single-target Drugs Sales by Product in 2024

11.5.6 Novartis FIC Single-target Drugs Sales by Application in 2024

11.5.7 Novartis FIC Single-target Drugs Sales by Geographic Area in 2024

11.5.8 Novartis FIC Single-target Drugs SWOT Analysis

11.5.9 Novartis Recent Developments

11.6 BMS

11.6.1 BMS Corporation Information

11.6.2 BMS Business Overview

11.6.3 BMS FIC Single-target Drugs Product Models, Descriptions and Specifications

11.6.4 BMS FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 BMS Recent Developments

11.7 ImmunoGen

11.7.1 ImmunoGen Corporation Information

11.7.2 ImmunoGen Business Overview

11.7.3 ImmunoGen FIC Single-target Drugs Product Models, Descriptions and Specifications

11.7.4 ImmunoGen FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 ImmunoGen Recent Developments

11.8 Sanofi

11.8.1 Sanofi Corporation Information

11.8.2 Sanofi Business Overview

11.8.3 Sanofi FIC Single-target Drugs Product Models, Descriptions and Specifications

11.8.4 Sanofi FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Sanofi Recent Developments

11.9 Immunocore

11.9.1 Immunocore Corporation Information

11.9.2 Immunocore Business Overview

11.9.3 Immunocore FIC Single-target Drugs Product Models, Descriptions and Specifications

11.9.4 Immunocore FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 Immunocore Recent Developments

11.10 Genentech

11.10.1 Genentech Corporation Information

11.10.2 Genentech Business Overview

11.10.3 Genentech FIC Single-target Drugs Product Models, Descriptions and Specifications

11.10.4 Genentech FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 Genentech Recent Developments

11.11 Eli Lilly

11.11.1 Eli Lilly Corporation Information

11.11.2 Eli Lilly Business Overview

11.11.3 Eli Lilly FIC Single-target Drugs Product Models, Descriptions and Specifications

11.11.4 Eli Lilly FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.11.5 Eli Lilly Recent Developments

11.12 Agios

11.12.1 Agios Corporation Information

11.12.2 Agios Business Overview

11.12.3 Agios FIC Single-target Drugs Product Models, Descriptions and Specifications

11.12.4 Agios FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.12.5 Agios Recent Developments

11.13 Boehringer Ingelheim

11.13.1 Boehringer Ingelheim Corporation Information

11.13.2 Boehringer Ingelheim Business Overview

11.13.3 Boehringer Ingelheim FIC Single-target Drugs Product Models, Descriptions and Specifications

11.13.4 Boehringer Ingelheim FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.13.5 Boehringer Ingelheim Recent Developments

11.14 Gilead

11.14.1 Gilead Corporation Information

11.14.2 Gilead Business Overview

11.14.3 Gilead FIC Single-target Drugs Product Models, Descriptions and Specifications

11.14.4 Gilead FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.14.5 Gilead Recent Developments

11.15 Mallinckrodt

11.15.1 Mallinckrodt Corporation Information

11.15.2 Mallinckrodt Business Overview

11.15.3 Mallinckrodt FIC Single-target Drugs Product Models, Descriptions and Specifications

11.15.4 Mallinckrodt FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.15.5 Mallinckrodt Recent Developments

11.16 Phathom

11.16.1 Phathom Corporation Information

11.16.2 Phathom Business Overview

11.16.3 Phathom FIC Single-target Drugs Product Models, Descriptions and Specifications

11.16.4 Phathom FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.16.5 Phathom Recent Developments

11.17 Dermavant Sciences

11.17.1 Dermavant Sciences Corporation Information

11.17.2 Dermavant Sciences Business Overview

11.17.3 Dermavant Sciences FIC Single-target Drugs Product Models, Descriptions and Specifications

11.17.4 Dermavant Sciences FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.17.5 Dermavant Sciences Recent Developments

11.18 Polarean lmaging

11.18.1 Polarean lmaging Corporation Information

11.18.2 Polarean lmaging Business Overview

11.18.3 Polarean lmaging FIC Single-target Drugs Product Models, Descriptions and Specifications

11.18.4 Polarean lmaging FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.18.5 Polarean lmaging Recent Developments

11.19 Marinus

11.19.1 Marinus Corporation Information

11.19.2 Marinus Business Overview

11.19.3 Marinus FIC Single-target Drugs Product Models, Descriptions and Specifications

11.19.4 Marinus FIC Single-target Drugs Sales, Price, Revenue and Gross Margin (2020-2025)

11.19.5 Marinus Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 FIC Single-target Drugs Industry Chain

12.2 FIC Single-target Drugs Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 FIC Single-target Drugs Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 FIC Single-target Drugs Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 FIC Single-target Drugs Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global FIC Single-target Drugs Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global FIC Single-target Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global FIC Single-target Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global FIC Single-target Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global FIC Single-target Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global FIC Single-target Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global FIC Single-target Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global FIC Single-target Drugs Sales by Region (2020-2025) & (K Units)

Table 8. Global FIC Single-target Drugs Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global FIC Single-target Drugs Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global FIC Single-target Drugs Sales Share by Manufacturers (2020-2025)

Table 12. Global FIC Single-target Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global FIC Single-target Drugs Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global FIC Single-target Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in FIC Single-target Drugs as of 2024)

Table 16. Global FIC Single-target Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global FIC Single-target Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers FIC Single-target Drugs Manufacturing Base and Headquarters

Table 19. Global FIC Single-target Drugs Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global FIC Single-target Drugs Sales by Type (2020-2025) & (K Units)

Table 23. Global FIC Single-target Drugs Sales by Type (2026-2031) & (K Units)

Table 24. Global FIC Single-target Drugs Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global FIC Single-target Drugs Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global FIC Single-target Drugs ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global FIC Single-target Drugs Sales by Application (2020-2025) & (K Units)

Table 29. Global FIC Single-target Drugs Sales by Application (2026-2031) & (K Units)

Table 30. FIC Single-target Drugs High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global FIC Single-target Drugs Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global FIC Single-target Drugs Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global FIC Single-target Drugs ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America FIC Single-target Drugs Growth Accelerators and Market Barriers

Table 37. North America FIC Single-target Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America FIC Single-target Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe FIC Single-target Drugs Growth Accelerators and Market Barriers

Table 40. Europe FIC Single-target Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe FIC Single-target Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific FIC Single-target Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific FIC Single-target Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific FIC Single-target Drugs Growth Accelerators and Market Barriers

Table 45. Southeast Asia FIC Single-target Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America FIC Single-target Drugs Investment Opportunities and Key Challenges

Table 47. Central and South America FIC Single-target Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa FIC Single-target Drugs Investment Opportunities and Key Challenges

Table 49. Middle East and Africa FIC Single-target Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Pfizer Corporation Information

Table 51. Pfizer Description and Major Businesses

Table 52. Pfizer Product Models, Descriptions and Specifications

Table 53. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Pfizer Sales Value Proportion by Product in 2024

Table 55. Pfizer Sales Value Proportion by Application in 2024

Table 56. Pfizer Sales Value Proportion by Geographic Area in 2024

Table 57. Pfizer FIC Single-target Drugs SWOT Analysis

Table 58. Pfizer Recent Developments

Table 59. Johnson & Johnson Corporation Information

Table 60. Johnson & Johnson Description and Major Businesses

Table 61. Johnson & Johnson Product Models, Descriptions and Specifications

Table 62. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. Johnson & Johnson Sales Value Proportion by Product in 2024

Table 64. Johnson & Johnson Sales Value Proportion by Application in 2024

Table 65. Johnson & Johnson Sales Value Proportion by Geographic Area in 2024

Table 66. Johnson & Johnson FIC Single-target Drugs SWOT Analysis

Table 67. Johnson & Johnson Recent Developments

Table 68. Merck Corporation Information

Table 69. Merck Description and Major Businesses

Table 70. Merck Product Models, Descriptions and Specifications

Table 71. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Merck Sales Value Proportion by Product in 2024

Table 73. Merck Sales Value Proportion by Application in 2024

Table 74. Merck Sales Value Proportion by Geographic Area in 2024

Table 75. Merck FIC Single-target Drugs SWOT Analysis

Table 76. Merck Recent Developments

Table 77. Roche Corporation Information

Table 78. Roche Description and Major Businesses

Table 79. Roche Product Models, Descriptions and Specifications

Table 80. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Roche Sales Value Proportion by Product in 2024

Table 82. Roche Sales Value Proportion by Application in 2024

Table 83. Roche Sales Value Proportion by Geographic Area in 2024

Table 84. Roche FIC Single-target Drugs SWOT Analysis

Table 85. Roche Recent Developments

Table 86. Novartis Corporation Information

Table 87. Novartis Description and Major Businesses

Table 88. Novartis Product Models, Descriptions and Specifications

Table 89. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Novartis Sales Value Proportion by Product in 2024

Table 91. Novartis Sales Value Proportion by Application in 2024

Table 92. Novartis Sales Value Proportion by Geographic Area in 2024

Table 93. Novartis FIC Single-target Drugs SWOT Analysis

Table 94. Novartis Recent Developments

Table 95. BMS Corporation Information

Table 96. BMS Description and Major Businesses

Table 97. BMS Product Models, Descriptions and Specifications

Table 98. BMS Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. BMS Recent Developments

Table 100. ImmunoGen Corporation Information

Table 101. ImmunoGen Description and Major Businesses

Table 102. ImmunoGen Product Models, Descriptions and Specifications

Table 103. ImmunoGen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. ImmunoGen Recent Developments

Table 105. Sanofi Corporation Information

Table 106. Sanofi Description and Major Businesses

Table 107. Sanofi Product Models, Descriptions and Specifications

Table 108. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Sanofi Recent Developments

Table 110. Immunocore Corporation Information

Table 111. Immunocore Description and Major Businesses

Table 112. Immunocore Product Models, Descriptions and Specifications

Table 113. Immunocore Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. Immunocore Recent Developments

Table 115. Genentech Corporation Information

Table 116. Genentech Description and Major Businesses

Table 117. Genentech Product Models, Descriptions and Specifications

Table 118. Genentech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. Genentech Recent Developments

Table 120. Eli Lilly Corporation Information

Table 121. Eli Lilly Description and Major Businesses

Table 122. Eli Lilly Product Models, Descriptions and Specifications

Table 123. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 124. Eli Lilly Recent Developments

Table 125. Agios Corporation Information

Table 126. Agios Description and Major Businesses

Table 127. Agios Product Models, Descriptions and Specifications

Table 128. Agios Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 129. Agios Recent Developments

Table 130. Boehringer Ingelheim Corporation Information

Table 131. Boehringer Ingelheim Description and Major Businesses

Table 132. Boehringer Ingelheim Product Models, Descriptions and Specifications

Table 133. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 134. Boehringer Ingelheim Recent Developments

Table 135. Gilead Corporation Information

Table 136. Gilead Description and Major Businesses

Table 137. Gilead Product Models, Descriptions and Specifications

Table 138. Gilead Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 139. Gilead Recent Developments

Table 140. Mallinckrodt Corporation Information

Table 141. Mallinckrodt Description and Major Businesses

Table 142. Mallinckrodt Product Models, Descriptions and Specifications

Table 143. Mallinckrodt Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 144. Mallinckrodt Recent Developments

Table 145. Phathom Corporation Information

Table 146. Phathom Description and Major Businesses

Table 147. Phathom Product Models, Descriptions and Specifications

Table 148. Phathom Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 149. Phathom Recent Developments

Table 150. Dermavant Sciences Corporation Information

Table 151. Dermavant Sciences Description and Major Businesses

Table 152. Dermavant Sciences Product Models, Descriptions and Specifications

Table 153. Dermavant Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 154. Dermavant Sciences Recent Developments

Table 155. Polarean lmaging Corporation Information

Table 156. Polarean lmaging Description and Major Businesses

Table 157. Polarean lmaging Product Models, Descriptions and Specifications

Table 158. Polarean lmaging Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 159. Polarean lmaging Recent Developments

Table 160. Marinus Corporation Information

Table 161. Marinus Description and Major Businesses

Table 162. Marinus Product Models, Descriptions and Specifications

Table 163. Marinus Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 164. Marinus Recent Developments

Table 165. Key Raw Materials Distribution

Table 166. Raw Materials Key Suppliers

Table 167. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 168. Milestones in Production Technology Evolution

Table 169. Distributors List

Table 170. Market Trends and Market Evolution

Table 171. Market Drivers and Opportunities

Table 172. Market Challenges, Risks, and Restraints

Table 173. Research Programs/Design for This Report

Table 174. Key Data Information from Secondary Sources

Table 175. Key Data Information from Primary Sources

List of Figures

Figure 1. FIC Single-target Drugs Product Picture

Figure 2. Global FIC Single-target Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. RORγ Covalent Inhibitors Product Picture

Figure 4. Citron Inhibitors Product Picture

Figure 5. ALK2 Inhibitors Product Picture

Figure 6. GCN2 Agonists Product Picture

Figure 7. Others Product Picture

Figure 8. Global FIC Single-target Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 9. Hospital

Figure 10. Clinic

Figure 11. Other

Figure 12. FIC Single-target Drugs Report Years Considered

Figure 13. Global FIC Single-target Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 15. Global FIC Single-target Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 16. Global FIC Single-target Drugs Revenue Market Share by Region (2020-2031)

Figure 17. Global FIC Single-target Drugs Sales (2020-2031) & (K Units)

Figure 18. Global FIC Single-target Drugs Sales (CAGR) by Region (2020-2031) (K Units)

Figure 19. Global FIC Single-target Drugs Sales Market Share by Region (2020-2031)

Figure 20. Top 5 and Top 10 Manufacturers FIC Single-target Drugs Sales Volume Market Share in 2024

Figure 21. Global FIC Single-target Drugs Revenue Market Share Ranking (2024)

Figure 22. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 23. RORγ Covalent Inhibitors Revenue Market Share by Manufacturer in 2024

Figure 24. Citron Inhibitors Revenue Market Share by Manufacturer in 2024

Figure 25. ALK2 Inhibitors Revenue Market Share by Manufacturer in 2024

Figure 26. GCN2 Agonists Revenue Market Share by Manufacturer in 2024

Figure 27. Others Revenue Market Share by Manufacturer in 2024

Figure 28. Global FIC Single-target Drugs Sales Market Share by Type (2020-2031)

Figure 29. Global FIC Single-target Drugs Revenue Market Share by Type (2020-2031)

Figure 30. Global FIC Single-target Drugs Sales Market Share by Application (2020-2031)

Figure 31. Global FIC Single-target Drugs Revenue Market Share by Application (2020-2031)

Figure 32. North America FIC Single-target Drugs Sales YoY (2020-2031) & (K Units)

Figure 33. North America FIC Single-target Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 34. North America Top 5 Manufacturers FIC Single-target Drugs Sales Revenue (US$ Million) in 2024

Figure 35. North America FIC Single-target Drugs Sales Volume (K Units) by Type (2020- 2031)

Figure 36. North America FIC Single-target Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 37. North America FIC Single-target Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 38. North America FIC Single-target Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 39. US FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 40. Canada FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 41. Mexico FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 42. Europe FIC Single-target Drugs Sales YoY (2020-2031) & (K Units)

Figure 43. Europe FIC Single-target Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 44. Europe Top 5 Manufacturers FIC Single-target Drugs Sales Revenue (US$ Million) in 2024

Figure 45. Europe FIC Single-target Drugs Sales Volume (K Units) by Type (2020-2031)

Figure 46. Europe FIC Single-target Drugs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 47. Europe FIC Single-target Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 48. Europe FIC Single-target Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 49. Germany FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 50. France FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 51. U.K. FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 52. Italy FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 53. Russia FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 54. Asia-Pacific FIC Single-target Drugs Sales YoY (2020-2031) & (K Units)

Figure 55. Asia-Pacific FIC Single-target Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 56. Asia-Pacific Top 8 Manufacturers FIC Single-target Drugs Sales Revenue (US$ Million) in 2024

Figure 57. Asia-Pacific FIC Single-target Drugs Sales Volume (K Units) by Type (2020- 2031)

Figure 58. Asia-Pacific FIC Single-target Drugs Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 59. Asia-Pacific FIC Single-target Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 60. Asia-Pacific FIC Single-target Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 61. Indonesia FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 62. Japan FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 63. South Korea FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 64. China Taiwan FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 65. India FIC Single-target Drugs Revenue (2020-2031) & (US$ Million)

Figure 66. Central and South America FIC Single-target Drugs Sales YoY (2020-2031) & (K Units)

Figure 67. Central and South America FIC Single-target Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 68. Central and South America Top 5 Manufacturers FIC Single-target Drugs Sales Revenue (US$ Million) in 2024

Figure 69. Central and South America FIC Single-target Drugs Sales Volume (K Units) by Type (2021-2031)

Figure 70. Central and South America FIC Single-target Drugs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 71. Central and South America FIC Single-target Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 72. Central and South America FIC Single-target Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 73. Brazil FIC Single-target Drugs Revenue (2020-2025) & (US$ Million)

Figure 74. Argentina FIC Single-target Drugs Revenue (2020-2025) & (US$ Million)

Figure 75. Middle East, and Africa FIC Single-target Drugs Sales YoY (2020-2031) & (K Units)

Figure 76. Middle East and Africa FIC Single-target Drugs Revenue YoY (2020-2031) & (US$ Million)

Figure 77. Middle East and Africa Top 5 Manufacturers FIC Single-target Drugs Sales Revenue (US$ Million) in 2024

Figure 78. Middle East and Africa FIC Single-target Drugs Sales Volume (K Units) by Type (2021-2031)

Figure 79. South America FIC Single-target Drugs Sales Revenue (US$ Million) by Type (2020-2031)

Figure 80. Middle East and Africa FIC Single-target Drugs Sales Volume (K Units) by Application (2020-2031)

Figure 81. Middle East and Africa FIC Single-target Drugs Sales Revenue (US$ Million) by Application (2020-2031)

Figure 82. GCC Countries FIC Single-target Drugs Revenue (2020-2025) & (US$ Million)

Figure 83. Turkey FIC Single-target Drugs Revenue (2020-2025) & (US$ Million)

Figure 84. Egypt FIC Single-target Drugs Revenue (2020-2025) & (US$ Million)

Figure 85. South Africa FIC Single-target Drugs Revenue (2020-2025) & (US$ Million)

Figure 86. FIC Single-target Drugs Industry Chain Mapping

Figure 87. Regional FIC Single-target Drugs Manufacturing Base Distribution (%)

Figure 88. Global FIC Single-target Drugs Production Market Share by Region (2020-2031)

Figure 89. FIC Single-target Drugs Production Process

Figure 90. Regional FIC Single-target Drugs Production Cost Structure

Figure 91. Channels of Distribution (Direct Vs Distribution)

Figure 92. Bottom-up and Top-down Approaches for This Report

Figure 93. Data Triangulation

Figure 94. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-18T17751

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Pioglitazone Hydrochloride Capsules Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-10K20152

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global FIC Single-target Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-15K17940

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

Global Macitentan Tablets Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-37W17851

Tue Oct 14 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global FIC Single-target Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

Published Date: October 2025

Report Code: QYRE-Auto-15K17940

Global FIC Single-target Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031

FEATURED COMPANIES

FIC Single-target Drugs Market

Report Includes:

Scope of FIC Single-target Drugs Market Report

Chapter Outline

FAQ for this report

Who are the main players in the FIC Single-target Drugs Market report?

What are the Application segmentation covered in the FIC Single-target Drugs Market report?

What are the Type segmentation covered in the FIC Single-target Drugs Market report?

FEATURED COMPANIES

RELATED REPORTS